• Policy
• Rationalization of expedited review of new pharmaceuticals
• by Lee, Hye-Kyung Jun 20, 2023 05:35am

• Company
• ALS drug Teglutik may be prescribed at general hospitals
• by Eo, Yun-Ho Jun 20, 2023 05:35am

• Company
• SK Biopharmaceuticals’ Cenobamate approved in Canada
• by Chon, Seung-Hyun Jun 19, 2023 06:00am

• Policy
• 100 billion won more for new drug 500 billion won megafund
• by Lee, Hye-Kyung Jun 19, 2023 06:00am

• Company
• ADHD drug Strattera discontinues supply in Korea
• by Kim, Jin-Gu Jun 19, 2023 06:00am

• Company
• Epkinly designated as an orphan drug in Korea
• by Eo, Yun-Ho Jun 19, 2023 06:00am

• Company
• Forxiga generics occupy 20% of mkt 2 mths into their release
• by Kim, Jin-Gu Jun 19, 2023 05:59am

• Policy
• Awareness of Korean pharmaceuticals, ranked 7th out of 13
• by Lee, Hye-Kyung Jun 16, 2023 05:55am

• Policy
• RMP evaluation cycle Up to 3 yrs What items can be changed?
• by Lee, Hye-Kyung Jun 16, 2023 05:55am

• Company
• Lipiodol is in stable supply despite price cuts
• by Nho, Byung Chul Jun 16, 2023 05:55am